For patients with obesity and prediabetes, three years of tirzepatide yields substantial and sustained weight reductio ...

Tirzepatide by Eli Lilly reduces heart failure risk in adults with HFpEF and obesity, showing promising results for both ...

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking ...

The detailed results were published in The New England Journal of Medicine and were presented at ObesityWeek 2024.

Payers and employers have tightened access to the glucagon-like peptide-1 receptor agonist class once these therapies became ...

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a reduced combined risk of worsening heart failure ...

SUMMT has shown for the first time that a drug can reduce major heart failure clinical outcomes in patients with heart ...

Tirzepatide demonstrated sustained average weight loss of 22.9% (15 mg dose) through the three-year treatment period. The study showed an association of tirzepatide treatment with improved ...

By Dr. Sushama R. Chaphalkar, PhD. A long-term study reveals how tirzepatide not only cuts weight but also slashes diabetes ...

New medication that can cut body weight by 23% could radically reduce the number of people who are obese. Tirzepatide is ...